ReViral, a clinical-stage biopharmaceutical company focused on discovering and developing antiviral therapeutics that target (RSV) respiratory syncytial virus has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Sisunatovir is orally administered and is for the treatment of patients with serious RSV infection. Richmond Pharmacology is proud to have supported the development by conducting the First in Human Study earlier in the drug development.

RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Fast Track is a process intended to facilitate the development and expediate the review of drug candidates that treat serious conditions and fill an unmet medical need.

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event